We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Fintel reports that on June 26, 2024, Guggenheim downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from Buy to Neutral. Analyst Price Forecast Suggests 109.23% Upside As of June 12, 2024, the ...

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Piper Sandler on September 11, 2025. The analyst firm set a price target for $15.00 expecting TXG to rise to within 12 months (a ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded ...

In my last 10x Genomics (NASDAQ:TXG) article, I discussed how the ticker had been under relentless selling pressure, dropping from $209 in June 2021 to around $20 at the time of publication. 10x had ...

ClearBridge Investments, an investment management firm, published its “All Cap Growth Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge All Cap ...